Tag Archives: Marie Curie

Uncategorized

Harriet Brooks’ great-great niece to inspire next generation of women in science

Canada’s first female nuclear physicist Harriet Brooks

Harriet Brooks was the first Canadian female nuclear physicist, who worked as a graduate student with Sir Ernest Rutherford at McGill University around the beginning of the 20th century.

She was among the first persons to discover radon and to try to determine its atomic mass.

Well known in Canadian nuclear circles, Brooks is not a household name like Marie Curie, under whose supervision Brooks briefly worked.

While Canadian Nuclear Laboratories recently named a nuclear research laboratory at Chalk River in her name and she is a member of the Canadian Science and Engineering Hall of Fame, she hasn’t made an impact in the non-academic and non-science culture like Curie, who was honoured, for example, with a Google Doodle on the anniversary of her birth.

Now, 85 years after she passed away, one of her descendants is trying to bring her story to life on stage.

WONDER is a stage production in development about the gender barriers faced by Brooks. It is the first play written by Canadian actor Ellen Denny, Brooks’ great-great-niece.

“With this project, I hope to honour the countless women in science who have been silenced, and invigorate those who continue the fight for gender equity,” says Denny.

“It is also an important goal of mine to connect this historical science story and play of Harriet Brooks with the contemporary science community.”

Opening of the Harriet Brooks building at Canadian Nuclear Laboratories

Brooks left the world of physics at the peak of her career upon marriage to assume the occupation of wife and mother.

In an interview with Maclean’s magazine, Geoff Rayner-Canham, a chemistry professor at Newfoundland’s Memorial University who has written about Brooks, explained why she left the science community.

“What happened was that she got engaged to a physicist at Barnard College, which is an old women’s college in the States, and she told the dean she was planning to marry. The dean sent a letter back saying that she was not willing to have anyone in the department who put her work second, but didn’t think it was appropriate for a married woman to put her career before her family.”

While what happened to Brooks could be attributed to social mores at the time, Denny believes her story is relevant to the barriers that still exist for women today who balance career with family.

Canadian actress Ellen Denny

In a slick video on her Kickstarter campaign page she launched to fund the production, Denny lists some current stats on gender and science. For example, in 2010, just 12.4 per cent of physics faculty at Canadian universities were women and only 30 per cent of female high school students take physics, compared to 60 per cent of male high school students.

“The play WONDER is a chance to build a bridge between the science and arts communities, and to spark discussion about how to build workplaces with equitable opportunity for all,” she explains.

The reaction to Denny’s project has been positive so far. Her Kickstarter campaign to fund a workshop of the play has raised over $2,000, almost triple her original goal.

Before WONDER is ready for its premiere production it needs some time in the lab – in theatre this is called a “workshop.” One week of in-studio script development and physical exploration with a team of professional artists is slated for early 2019 and Denny is hard at work raising funds for this critical next step.

You can follow along with the development of WONDER on Twitter and #WonderThePlay.

Uncategorized

Nuclear Approach to Cancer Could Save Lives

While Tragically Hip front man Gord Downie may be the most recognized person to be living with glioblastoma, brain cancer affects hundreds of thousands of families every year. A bleak diagnosis, the five-year survival rate for patients aged 45 to 54 sits at just four per cent according to the Canadian Cancer Society.

However, there is reason to be hopeful. New research in nuclear medicine targets cancers like glioblastoma through an inside-out approach, giving patients a new lease on life. These small and mighty cancer fighters are known as alpha-emitting isotopes and unlike traditional radiation therapy, which blasts cells from the outside, alphas attack cancer from the inside, protecting healthy tissues while destroying diseased ones.

“It’s a magic bullet for people in the cancer field because it has the beauty of sparing healthy tissues and finding and weeding out tiny tumors,” according to Dr. Tom Ruth, Special Advisor, Emeritus, TRIUMF.

Recently, The Medical University of Warsaw beat out over 2,000 other submissions to win the Marie Curie Award from the European Association of Nuclear Medicine (EANM) for their work on alpha therapies. Their research indicated that the work of alpha therapies could extend the life of patients with brain cancer by almost two years compared to patients who weren’t treated by alpha radiation. Alpha-emitting isotopes, unlike their beta radiation counterparts, have higher energy and can only travel short distances which makes them ideal cancer fighters.

“Alpha particles fly very short distances so because of short penetration range in tissues you won’t destroy healthy cells,” stated Valery Radchenko, Research Scientist, TRIUMF.

Researchers at TRIUMF are mapping out alpha-emitting isotopes as a way of extending the life of cancer patients or curing them all-together. Alpha-therapy is thought to be especially effective for those with late-stage or metastasized cancers (cancer that has spread from one part of the body to another).

“The key to alpha is to combine them with the right biomolecule to target the cancer cells. If you can find a way to get an alpha-emitting isotope to a tumor you can potentially cure the cancer,” said Radchenko.

While alpha-therapy could be a game changer in the fight against cancer, researchers need wider access to the alpha particles and closer partnerships with the health care system in order to complete the preliminary tests required to bring alpha-therapies to the mainstream market.

“The main problem is lack of facilities for the production of a clinically relevant amount of alpha emitters. There are just several around the world so they aren’t readily available,” stressed Radchenko.

Uncategorized

Nuclear Fun Fact: Harriet Brooks

Harriet Brooks